Navigation Links
Microsoft to Showcase Innovative Solutions for Health Plans at AHIP Institute 2008
Date:6/16/2008

Microsoft demonstrates new technology for health plans aimed at increasing

customer satisfaction and driving new business opportunities.
SAN FRANCISCO, June 16 /PRNewswire-FirstCall/ --

What: At America's Health Insurance Plans (AHIP) Institute 2008,

Microsoft Corp. will showcase new solutions designed for the

health plans industry, such as the following:

o Driving business performance with Microsoft Office Business

Applications (OBAs)

-- Health plans are challenged with costly paper and manual

processes when responding to proposals. Microsoft will

highlight a demo titled Automating the Request for

Proposal (RFP) Process, an OBA designed to eliminate

"people as middleware" between productivity and

line-of-business applications.

o Improving customer experience with Microsoft unified

communications

-- Microsoft's unified communications suite enables health

plans to offer chat-based conversations with their

members, conducted virtually or with a live agent,

allowing consumers to communicate using their own words.

Microsoft will demonstrate how this can help improve

first call resolution rates and shorten average call and

hold times, resulting in a quick return on investment.

o Accelerate innovation and process improvement with Microsoft

Office Visio

-- Health plan business managers can significantly accelerate

innovation by reducing the complexity and cost of

analyzing and improving business and care processes. This

demonstration will feature a simple, Office Visio-based
'/>"/>

SOURCE Microsoft Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners
2. Microsoft Announces Alliance to Accelerate Consumer-Centered Delivery of Health and Human Services
3. MediKeeper Forms Alliance With Microsofts HealthVault
4. Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform
5. Kaiser Permanente and Microsoft Empower Consumers to Take Charge of Their Health
6. Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault
7. Microsoft HealthVault Be Well Fund Increased to $4.5 Million
8. Yales Scassellati gets Microsoft breakthrough research award for robotics
9. Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety
10. Microsoft Health & Life Sciences Developer and Solutions Conference to Feature the Latest Microsoft-Based Software Solutions
11. Scientists Explore Human Gene Pool With Help From Microsoft Research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 1Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 2Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 1Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 2Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 4Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 5Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 6Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 7Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 8Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 9Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 10Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 11Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 12Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 13Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 14Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 15Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 16Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 17Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 18Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 19Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 20Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 21Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 22Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 23Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 24Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 25Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 26Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 27Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 28U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 1U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 2U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 3